



ANUPAM RASAYAN INDIA LTD.

ARILSLDSTX20250213075

Date: February 13, 2025

To, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001, India SCRIP CODE: 543275	To, National Stock Exchange of India Limited 'Exchange Plaza', C-1, Block-G, Bandra Kurla Complex, Bandra (East), Mumbai-400051, India SYMBOL: ANURAS
---	--

Dear Sir/Madam,

Subject: Press Release Intimation of Anupam Rasayan India Limited (the "Company")

Pursuant to Regulation 30 and other applicable regulations, if any, of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed Press Release to be issued by the Company today i.e., February 13, 2025, regarding the Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2024, approved by the Board of Directors of the Company.

This Press Release will also be available on the website of the Company at www.anupamrasayan.com.

We request you to kindly take note the same.

Thanking you,

Yours Faithfully,

For Anupam Rasayan India Limited

Anand Desai
Managing Director
DIN: 00038442

Encl.: As above



Anupam Rasayan India Limited Reports Q3 & 9M FY25 Results

Q3FY25 Total Revenue of ₹3,866 Mn; YOY Growth at 30%

Surat, February 13, 2025: Anupam Rasayan India Ltd. (BSE- 543275, NSE- ANURAS, ISIN: INE930P01018), one of India's leading custom synthesis and specialty chemical player, has announced its financial results for the quarter December 31, 2024.

Consolidated Financial Highlights for nine month ended December 31, 2024:

- Total revenue for 9MFY25 was at ₹9,428 million as compared to ₹10,923 million in 9MFY24; down 14% YoY.
- EBITDA (incl. other income) was at ₹2,624 million in 9MFY25 as compared to ₹3,062 million in 9MFY24, this would translate into 28% EBITDA margin in 9MFY25.
- Profit After Tax was at ₹970 million in 9MFY25 as compared to ₹1,270 million in 9MFY24.

Consolidated Financial Highlights for Quarter ended December 31, 2024:

- Total revenue for Q3FY25 was at ₹3,866 million as compared to ₹2,979 million in Q3FY24; up 30% YoY.
- EBITDA (incl. other income) was at ₹1,208 million in Q3FY25 as compared to ₹815 million in Q3FY24, up 48% and this would translate into 31% EBITDA margin in this quarter.
- Profit After Tax was at ₹542 million in Q3FY25 as compared to ₹260 million in Q3FY24; up 108% YoY.

Speaking on the performance, Mr Anand Desai, Managing Director, Anupam Rasayan commented, "Our Pharma and Polymer segments, which have emerged as key growth drivers, continue to strengthen their contribution to our revenue. Both the segments coupled with strong performance of Tanfac led to significant growth this quarter, fueling a robust 31% QoQ revenue growth in Q3FY25 on a consolidated basis. For the full year, we expect them to play a substantial role in overall revenue, with this upward trend projected to continue into FY26. Additionally, the Agrochemical segment has shown signs of recovery, particularly in the European market."

"With strong demand momentum and expected off-take from our customers, we anticipate regaining our growth trajectory in the next financial year, aiming for a 30-35% revenue increase in FY26."

About Anupam Rasayan India Ltd. (ARIL):

Anupam Rasayan India Ltd (ARIL) is one of the leading companies engaged in the custom synthesis (CSM) and manufacturing of specialty chemicals in India. Incorporated in 1984, the speciality chemicals major has two verticals: Life science related Specialty Chemicals comprising products related to Agrochemicals, Personal Care and Pharmaceuticals, Other Specialty Chemicals comprising Polymer Additives. The Company caters to a diverse base of Indian and global customers. It is currently manufacturing products for over 75 domestic and international customers, including 31 multinational companies. The Company operates via its six manufacturing facilities in Gujarat, India, with four facilities located at Sachin, Surat and two located at Jhagadia, Bharuch with an aggregate installed capacity of about 30,000 MT, as of December 31, 2024. ARIL offers multistep synthesis and undertakes complex chemical reactions technologies, for a diverse base of Indian and global customers. The Company is focussed on developing in-house innovative processes for manufacturing products requiring complex chemistries and achieving cost optimization.

For further details, please get in touch with:

IR Contact:

Ernst & Young LLP

Krishna Patel

Email: krishna.patel2@in.ey.com

PR Contact:

Sanchi Yadav

Email: sanchi.yadav@adfactorspr.com

Phone: + 91 98336 40764